Glutamic acid decarboxylase (GAD) chimera and methods of use
The invention relates to a novel Glutamic Acid Decarboxylase (GAD). More specifically, novel DNA and protein sequences relating to GAD. Additionally, the invention discloses a novel composition and related methods for treating neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, epilepsy, and the like, using viral and non-viral delivery systems that deliver therapeutic agents to specific regions of the brain. More specifically, using an adeno-associated viral vector to deliver a nucleotide sequence encoding a novel glutamic acid decarboxylase (GAD) to specific regions of the brain that are over stimulated or disinhibited in various diseases, including neurodegenerative diseases.
1. A chimeric nucleic acid comprising a nucleic acid sequence encoding a polypeptide with glutamic acid decarboxylase (GAD) activity having an amino-terminal portion of GAD65 and a carboxy-terminal portion of GAD67, wherein the polypeptide has a 99% or more homology with SEQ ID NO: 4.
2. A chimeric nucleic acid comprising a nucleic acid sequence encoding a polypeptide with glutamic acid decarboxylase (GAD) activity having an amino-terminal portion of GAD65 and a carboxy-terminal portion of GAD67, wherein the nucleic acid sequence has a 95% or more identity with SEQ ID NO: 3.
3. The chimeric nucleic acid of claim 2 , wherein the nucleic acid sequence has a 99% or more identity with SEQ ID NO: 3.
4. The chimeric nucleic acid of claim 1 , wherein the encoded GAD polypeptide comprises the amino acid sequence of SEQ. ID NO: 4.
5. A vector comprising the chimeric nucleic acid sequence of claim 1 .
6. A vector, comprising the chimeric nucleic acid sequence of claim 1 .
7. The vector of claim 5 , wherein the vector is a viral vector selected from the group consisting of adenovirus vectors, adeno-associated virus vectors, herpes virus vectors, parvovirus vectors, and lentivirus vectors.
8. A medicament comprising the chimeric nucleic acid according to claim 1 , or the vector according to claim 5 .
9. A pharmaceutical composition comprising:
the chimeric nucleic acid according to claim 1 , or the vector according to claim 5 ; and
a pharmaceutically or veterinary acceptable carrier or diluent.
10. A method of altering expression of glutamic acid decarboxylase (GAD) in a region of the central nervous system (CNS) of a subject with a neurodegenerative disease comprising:
identifying a target site in the CNS that requires modification;
delivering the chimeric nucleic acid of claim 1 to the target site in the CNS; and
expressing a polypeptide encoded by said chimeric nucleic acid in the target site, thereby altering GAD expression in the region of the CNS.
11. The method of claim 10 , wherein the target site in the central nervous system is a region of a brain.
12. The method of claim 11 , wherein the region of the brain is selected from the group consisting of basal ganglia, subthalamic nucleus (STN), pedunculopontine nucleus (PPN), substantia nigra (SN), thalamus, hippocampus, amygdala, hypothalamus, cortex, and combinations thereof.
13. The method of claim 10 , wherein the neurodegenerative disease is selected from the group consisting of Parkinson's disease, Alzheimer's disease, senile dementia, Amyloid Lateral Schlerosis (ALS), and epilepsy.
14. The method of claim 10 , wherein the step of delivering the chimeric nucleic acid comprises administering the pharmaceutical composition of claim 9 .
15. The method of claim 10 , wherein step of expressing the polypeptide comprises treating the neurodegenerative disease in the subject by altering GAD expression in the region of the CNS to improve the neurodegenerative disease.
16. A method of altering expression of glutamic acid decarboxylase (GAD) in a region of the central nervous system (CNS) of a subject with a neurodegenerative disease comprising:
identifying a target site in the CNS that requires modification;
delivering the chimeric nucleic acid of claim 2 to the target site in the CNS; and
expressing a polypeptide encoded by said chimeric nucleic acid in the target site, thereby altering GAD expression in the region of the CNS.
17. The method of claim 16 , wherein the target site in the central nervous system is a region of a brain.
18. The method of claim 17 , wherein the region of the brain is selected from the group consisting of basal ganglia, subthalamic nucleus (STN), pedunculopontine nucleus (PPN), substantia nigra (SN), thalamus, hippocampus, amygdala, hypothalamus, cortex, and combinations thereof.
19. The method of claim 16 , wherein the neurodegenerative disease is selected from the group consisting of Parkinson's disease, Alzheimer's disease, senile dementia, Amyloid Lateral Schlerosis (ALS), and epilepsy.
20. The method of claim 16 , wherein step of expressing the polypeptide comprises treating the neurodegenerative disease in the subject by altering GAD expression in the region of the CNS to improve the neurodegenerative disease.
21. The vector of claim 6 , wherein the vector is a viral vector selected from the group consisting of adenovirus vectors, adeno-associated virus vectors, herpes virus vectors, parvovirus vectors, and lentivirus vectors.
22. A medicament comprising the chimeric nucleic acid according to claim 2 , or the vector according to claim 6 .
23. A pharmaceutical composition comprising:
the chimeric nucleic acid according to claim 2 , or the vector according to claim 6 ; and
a pharmaceutically or veterinary acceptable carrier or diluent.